The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Natali D, Girerd B, Montani D, Soubrier F, Simonneau G, Humbert M, Sitbon O

Pulmonary arterial hypertension in a patient with Cowden syndrome and anorexigen exposure.

Chest. 2011;140(4):1066-1068

Frachon I, Etienne Y, Jobic Y, Le Gal G, Humbert M, Leroyer C

Benfluorex and unexplained valvular heart disease: a case-control study.

PloS one. 2010;5(4):e10128

Boutet K, Frachon I, Jobic Y, Gut-Gobert C, Leroyer C, Carlhant-Kowalski D, Sitbon O, Simonneau G, Humbert M

Fenfluramine-like cardiovascular side-effects of benfluorex.

The European respiratory journal. 2009;33(3):684-8

Kramer MS, Lane DA

Aminorex, dexfenfluramine, and primary pulmonary hypertension.

Journal of clinical epidemiology. 1998;51(4):361-4

Atanassoff PG, Weiss BM, Schmid ER, Tornic M

Pulmonary hypertension and dexfenfluramine.

Lancet (London, England). 1992;339(8790):436